News

Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers — including Dr. Michael Geschwind, who spoke with Alzheimer’s News Today — think has the potential to revolutionize…

During the American Chemical Society annual meeting, leading international researchers shared promising findings of 24 studies that looked at the beneficial effects of natural products on brain health and on the prevention of Alzheimer’s and other neurodegenerative diseases. For the first time, the beneficial effects of pure maple syrup…

The National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both part of the National Institutes of Health (NIH), have launched the Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M²OVE-AD) Consortium to better understand how the body’s vascular system, its network of large and…

Blueberries, a “super fruit” known to decrease the risk of cancer and heart disease, may also be of benefit against Alzheimer’s disease, according to findings recently presented at the 251st National Meeting & Exposition of the American Chemical Society (ACS). Blueberries are loaded with antioxidants, which, according to researchers, could…

CurePSP is a Maryland-based nonprofit organization that focuses on neurodegenerative diseases that strike when people are in their 50s to 70s, including Alzheimer’s disease. PSP stands for progressive supranuclear palsy, which is a neurodegenerative disorder that impacts movement, walking, speech, balance, mood, vision, behavior, and cognition. Like Alzheimer’s, PSP is characterized by…

European scientists have demonstrated that a nutritional drink, Fortasyn Connect, does not benefit broad cognitive function to the degree expected, but it can help to conserve brain tissue and memory in early, or prodromal, Alzheimer’s disease patients. The clinical trial is part of the LipiDiDiet project, a large European study exploring the therapeutic and…

An editorial by a large number of senior Alzheimer’s researchers urges the scientific community to take a serious look at evidence pointing to the contribution of microbes in the development of Alzheimer’s disease – and calling for more clinical research. Published online in the Journal of Alzheimer’s Disease by…

Louisiana State University Health Sciences Center researchers in New Orleans have shown that TREM2, an innate immune receptor protein essential to the clearing of waste from the brain and retina, is diminished in age-related macular degeneration (AMD), identifying a key molecular pathway and possible therapeutic target. Loss of function of TREM2…

The buildup of amyloid beta plaques in Alzheimer’s disease is believed to result from patients’ inability to break down the protein. But a new study from Lund University, Sweden, showed that overproduction of amyloid beta is more common than previously thought, giving a more nuanced picture of Alzheimer’s pathology. A small number of Alzheimer’s…

Researchers at the University of California, Berkeley, were able to show for the first time the progressive stages of Alzheimer’s disease in healthy adults and patients with Alzheimer’s using PET scans. This shows positron emission tomography (PET) scans can be used as diagnostic and staging tools in patients suffering from…